Lymphadenopathy and Splenomegaly

  • Joshua M. Dorn
  • Avni Y. Joshi
  • Roshini S. AbrahamEmail author


  • Autoimmune lymphoproliferative syndrome (ALPS) is characterized by chronic nonmalignant lymphoproliferation, splenomegaly, autoimmunity and increased risk of lymphoma

  • ALPS results from defects in the FAS pathway of cellular apoptosis, and most often from mutations in the FAS gene itself

  • Elevation of TCRαβ+CD45+CD3+CD4CD8 DNT cells is a characteristic feature of ALPS, and elevated soluble FAS ligand, vitamin B12, IL-10, and IL-18 can also be seen

  • Treatment is guided by severity of disease and Sirolimus has been shown to be successful in children with ALPS


Direct antiglobulin test Autoimmune lymphoproliferative syndrome FAS 


  1. 1.
    Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, Rieux-Laucat F, Siegel RM, Su HC, Teachey DT, Rao VK. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116(14):e35–40.CrossRefGoogle Scholar
  2. 2.
    Oliveira JB. The expanding spectrum of the autoimmune lymphoproliferative syndromes. Curr Opin Pediatr. 2013;25(6):722–9.CrossRefGoogle Scholar
  3. 3.
    Bride K, Teachey D. Autoimmune lymphoproliferative syndrome: more than a FAScinating disease. F1000Research. 2017;6:1928.CrossRefGoogle Scholar
  4. 4.
    Bleesing JJ, Nagaraj CB, Zhang K. Autoimmune lymphoproliferative syndrome. 2006 Sep 14 [updated 2017 Aug 24]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [internet]. Seattle (WA): University of Washington, Seattle; 199302019.Google Scholar
  5. 5.
    Rensing-Ehl A, Janda A, Lorenz MR, Gladstone BP, Fuchs I, Abinun M, Albert M, Butler K, Cant A, Cseh AM, Ebinger M, Goldacker S, Hambleton S, Hebart H, Houet L, Kentouche K, Kuhnle I, Lehmberg K, Mejstrikova E, Niemeyer C, Minkov M, Neth O, Duckers G, Owens S, Rosler J, Schilling FH, Schuster V, Seidel MG, Smisek P, Sukova M, Svec P, Wiesel T, Gathmann B, Schwarz K, Vach W, Ehl S, Speckmann C. Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia. Haematologica. 2013;98(12):1948–55.CrossRefGoogle Scholar
  6. 6.
    Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016;127(1):17–28.CrossRefGoogle Scholar
  7. 7.
    Dowdell KC, Niemela JE, Price S, Davis J, Hornung RL, Oliveira JB, Puck JM, Jaffe ES, Pittaluga S, Cohen JI, Fleisher TA, Rao VK. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood. 2010;115(25):5164–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Joshua M. Dorn
    • 1
  • Avni Y. Joshi
    • 1
  • Roshini S. Abraham
    • 2
    Email author
  1. 1.Division of Allergic Diseases, Department of MedicineMayo ClinicRochesterUSA
  2. 2.Diagnostic Immunology Laboratory, Department of Pathology and Laboratory MedicineNationwide Children’s HospitalColumbusUSA

Personalised recommendations